The Clinical Discovery Group within the RNA Bioscience Initiative seeks to develop new RNA therapeutics for disease diagnosis and treatment.
RNAs are informative readouts of disease status: the presence or absence of particular RNAs and isoforms can be specific to particular pathologic conditions, e.g., infection, cancer, and ischemia. Because the transcriptomes of normal and diseased cell types are complex and often poorly characterized, the potential utility of RNAs as biomarkers has not been fully exploited. The advent of new high throughput technologies, especially massively parallel single-cell RNA sequencing, empowers our researchers to fill this void.
An exceptional feature of RNA therapeutics is their ability to target any RNA via complementary sequence, enabling therapies for many diseases. RNA therapies are becoming increasingly common mainstream clinical tools. The RBI recently partnered with Children's Hospital Colorado to develop antisense oligonucleotide therapies for pediatric neurogenetic diseases.
Recent RNA-based vaccines developed by Pfizer and Moderna for SARS-CoV-2 have demonstrated remarkable potency, possibly ushering in a new era of RNA-based immunological tools.
The Denver/Boulder area is a major hub of RNA biotechnology. Establishment of partnerships with local companies is a priority for the RBI Clinical Discovery Group.
|Tom Anchordoquy, PhDemail@example.com||Development of synthetic delivery systems for use in nucleic acids-based therapies|
|Susan Boackle, MDfirstname.lastname@example.org||Long non-coding RNAs as a target for treatment of systemic lupus erythematosus|
|Matthew Burchill, PhDemail@example.com||Disease therapeutics targeting lymphatic endothelial cells|
|Heide Ford, PhDfirstname.lastname@example.org||Small molecule drug design to inhibit Six1/Eya transcriptional complex in tumors|
|Elena Hsieh, MDemail@example.com||Development of improved diagnostics and therapeutic treatments for immune system disorders|
|Peter Kabos, MDfirstname.lastname@example.org||Improved diagnostics and therapeutics to address anti-endocrine therapy resistant breast cancers|
|Jeffrey Kieft, PhDemail@example.com||RNAs as targets for small-molecule or within mRNA-based therapies (with industry partners)|
|Martin McCarter, MDfirstname.lastname@example.org||Therapeutics to inhibit BCL2 family members in melanoma|
|Karen Moulton, MDemail@example.com||Modulation of PTEN to treat pathological vascular fibrosis|
|J. David Port, PhDfirstname.lastname@example.org||MicroRNAs in heart failure, cardiac transplantation and myocardial recovery|
|Yiqun Shellman, PhDemail@example.com||Exploration of miR-26a replacement as therapy for treating melanoma|
|Matt Taylor, MD, PhDfirstname.lastname@example.org||Antisense oligonucleotide mediated exon skipping (AON) to prevent early termination of titin as a treatment for heart failure|
|Rui Zhao, PhDemail@example.com||Small molecule drug design to inhibit Six1/Eya transcriptional complex in tumors|